Amgen (MIL:1AMGN) 3-Year Book Growth Rate : -10.60% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Amgen 3-Year Book Growth Rate?

Amgen's Book Value per Share for the quarter that ended in Dec. 2023 was €10.03.

During the past 12 months, Amgen's average Book Value per Share Growth Rate was 69.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -10.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was -14.70% per year. During the past 10 years, the average Book Value per Share Growth Rate was -14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Amgen was 69.30% per year. The lowest was -26.10% per year. And the median was 16.00% per year.

Competitive Comparison of Amgen's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Amgen's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Amgen's 3-Year Book Growth Rate falls into.

Amgen 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Amgen (MIL:1AMGN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Amgen 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Amgen's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (MIL:1AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (MIL:1AMGN) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (MIL:1AMGN) Headlines

No Headlines